- Stocks
- Healthcare
- NASDAQ: INO

Price (delayed)

$8.59

Market cap

$1.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$1.75B

Inovio Pharmaceuticals's debt has shrunk by 66% YoY and by 13% QoQ

INO's quick ratio has surged by 52% year-on-year and by 23% since the previous quarter

INO's revenue has soared by 147% year-on-year but it is down by 13% since the previous quarter

The gross profit has surged by 147% year-on-year but it has declined by 13% since the previous quarter

INO's net income has dropped by 53% year-on-year and by 13% since the previous quarter

What are the main financial stats of INO

Market
Valuations
Earnings

Shares outstanding

209.4M

Market cap

$1.8B

Enterprise value

$1.75B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.07

Price to sales (P/S)

269.36

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

270.95

Revenue

$6.46M

EBIT

-$181.86M

EBITDA

-$177.37M

Free cash flow

-$206.98M

Per share
Balance sheet
Liquidity

EPS

-$1.09

Free cash flow per share

-$1.02

Book value per share

$2.8

Revenue per share

$0.03

TBVPS

$3.17

Total assets

$654.86M

Total liabilities

$73.26M

Debt

$33.9M

Equity

$581.61M

Working capital

$546.9M

Debt to equity

0.06

Current ratio

14.17

Quick ratio

12.73

Net debt/EBITDA

0.28

Margins
Efficiency
Dividend

EBITDA margin

-2,747.8%

Gross margin

100%

Net margin

-2,916.7%

Operating margin

-2,345.5%

Return on assets

-36.3%

Return on equity

-48.5%

Return on invested capital

-52.8%

Return on capital employed

-29.7%

Return on sales

-2,817.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Inovio Pharmaceuticals stock price performed over time

Intraday

2.26%

1 week

3.74%

1 month

-4.77%

1 year

-55.81%

YTD

-2.94%

QTD

-7.34%

How have Inovio Pharmaceuticals's revenue and profit performed over time

Revenue

$6.46M

Gross profit

$6.46M

Operating income

-$151.4M

Net income

-$188.27M

Gross margin

100%

Net margin

-2,916.7%

INO's revenue has soared by 147% year-on-year but it is down by 13% since the previous quarter

The gross profit has surged by 147% year-on-year but it has declined by 13% since the previous quarter

INO's net income has dropped by 53% year-on-year and by 13% since the previous quarter

The company's operating margin rose by 43% YoY but it fell by 40% QoQ

What is Inovio Pharmaceuticals's growth rate over time

What is Inovio Pharmaceuticals stock price valuation

P/E

N/A

P/B

3.07

P/S

269.36

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

270.95

INO's EPS is up by 7% year-on-year

The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 10.2 and 66% less than its last 4 quarters average of 8.9

The equity has grown by 26% from the previous quarter

INO's revenue has soared by 147% year-on-year but it is down by 13% since the previous quarter

The P/S is 63% lower than the last 4 quarters average of 729.3 but 44% higher than the 5-year quarterly average of 187.5

How efficient is Inovio Pharmaceuticals business performance

INO's ROE has soared by 73% YoY and by 16% from the previous quarter

INO's return on assets is up by 41% year-on-year and by 4% since the previous quarter

INO's return on sales is up by 35% year-on-year but it is down by 32% since the previous quarter

The company's return on invested capital rose by 11% QoQ and by 7% YoY

What is INO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INO.

How did Inovio Pharmaceuticals financials performed over time

The total assets has soared by 93% year-on-year and by 21% since the previous quarter

INO's current ratio has soared by 66% YoY and by 25% QoQ

Inovio Pharmaceuticals's debt is 94% lower than its equity

The debt to equity has plunged by 89% YoY and by 25% from the previous quarter

Inovio Pharmaceuticals's debt has shrunk by 66% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.